The future of immune checkpoint therapy

4,384 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2017, background): “The observation suggests that patients with hypermutated tumors may have a more immunological reactive microenvironment that may be responsive to immune checkpoint inhibitors (Sharma and Allison, 2015).”
Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer (2019, methodology): “For the PARP inhibitor experiments, mice received one of the following treatments: (1) vehicle; (2) olaparib (50 mg/kg daily) 4 times per week; (3) anti–PD-L1 (300 μg) once per week; or (4) combination of olaparib and anti–PD-L1.”
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (2016, background): “be a target for a T cell response, the presence of immune suppressive factors in the tumor microenviroment that exclude T cells in tumors or that lead to alteration of T cell function, presence of immune suppressive cells such as T regulatory or myeloid-derived suppressor cells, or cancers that have”